Nursing Pharmacology Chapter 33-34: Cancer Chemotherapy Anti-Tumor Antibiotics Practice Questions
Click on the correct answer.
Doxorubicin clinical use(s):
- Treatment of multiple myeloma
- Treatment of lymphomas
- Both
- Neither
Clinical use(s) of doxorubicin:
- Adult sarcomas
- Pediatric sarcomas
- Both
- Neither
Doxorubicin administration is likely beneficial in treating osteogenic, soft-tissue sarcomas and Ewing sarcoma.
- True
- False
Concerning toxic effect(s) associated with daunorubicin and doxorubicin:
- A significant dose-limiting complication is myelosuppression.
- Reversible stomatitis and mucositis may occur.
- Doxorubicin administration may induce significant local toxicity in tissue that has been irradiated.
- A & B
- B & C
- A & C
- A, B & C
The most significant long-term toxicity due to administration of anthracyclines, e.g. daunorubicin and doxorubicin especially is cardiomyopathy.
- True
- False
Factor/factors associated with enhanced risk due to anthracycline administration includes/include:
- Myocardial radiation
- High-dose cyclophosphamide administration
- Concomitant administration of trastuzumab.
- A & B
- B & C
- A & C
- A, B & C
Epirubicin (Ellence) administration may be used as part of combination treatment of breast cancer.
- True
- False
This doxorubicin analog (semisynthetic) is only used for intravesicular bladder cancer treatment.
- Daunorubicin
- Idarubincin
- Valrubicin
- Mitoxantrone
Pegylated liposomal doxorubicin formulation (Doxil) clinical use/uses:
- Treatment of AIDS-related Kaposi sarcoma
- Multiple myeloma
- Ovarian cancer
- A & B
- B & C
- A & C
- A, B & C
Daunorubicin (cerubidine):
- Acute lymphoblastic leukemia
- Acute myelogenous leukemia
- Both
- Neither
If
you wish to return to the Table of Contents in ENGLISH, press
the RETURN button above. |
Otherwise, if the text is NOT displayed in English and
you are ready to leave this page,
Press here
to return to the Table of Contents
|